Graph AI secures $3 mn from Bessemer to automate drug safety monitoring

startup funding

Graph AI, a California-based startup aiming to modernise drug safety operations, has raised $3 million in seed funding from Bessemer Venture Partners to tackle inefficiencies in the $8 billion pharmacovigilance market.

The company’s flagship product, Graph Safety, uses context-aware AI to automate the detection and reporting of adverse drug events (ADEs), a process traditionally handled by large teams of pharmacology graduates manually combing through call transcripts, legal filings, and medical literature. The platform is already in use by enterprise clients and claims to deliver up to 70% efficiency gains and 90% faster regulatory reporting.

“Pharma companies are stuck with outdated tech and fragmented workflows,” said CEO Raghav Parvataraju. “We’re building a unified, AI-native safety platform that makes patient safety smarter, faster, and more connected.”

Founded in 2024 by Parvataraju and three other industry veterans from Infosys, Google, and Cisco, Graph AI is part of a growing cohort of AI-native challengers targeting legacy service models in life sciences. The startup’s approach replaces labour arbitrage with what Bessemer calls “intelligence arbitrage”—a shift from manual processing to scalable automation.

“Graph AI is redefining pharmacovigilance workflows with solutions that prioritize both accuracy and scalability,” said Nithin Kaimal, Partner and COO at Bessemer India. “We’re excited to back a team that’s turning compliance into a competitive advantage.”

With over 7,000 marketed drugs in its pipeline, Graph AI is positioning itself as a key player in the global push to modernize pharmacovigilance—an area increasingly under scrutiny from regulators and investors alike.